Immunogenetics of Endocrine Ophthalmopathy and Graves� Disease

2015 ◽  
pp. 11-19 ◽  
Author(s):  
Klaus Badenhoop ◽  
Horst Schleusener ◽  
Klaus Henning Usadel
Keyword(s):  
Graves Disease ◽  
Endocrine Ophthalmopathy

Role of cytokines, IL1-β and IL-10, in the development of endocrine ophthalmopathy in Graves’ disease

2021 ◽  
Vol 93 (4) ◽  
pp. 48-52
Author(s):  
Yu. V. Buldygina ◽  
◽  
H. A. Zamotaieva ◽  
G. M. Terekhova ◽  
N. M. Stepura ◽  
...  
Keyword(s):  
Graves Disease ◽  
Endocrine Ophthalmopathy

The clinical course of endocrine ophthalmopathy in patients presenting with Graves' disease depending on the effect of radioiodine therapy

2011 ◽  
Vol 57 (3) ◽  
pp. 17-20
Author(s):  
M S Sheremeta ◽  
N Iu Sviridenko ◽  
I M Belovalova ◽  
P I Garbuzov
Keyword(s):  
Radioiodine Therapy ◽  
Clinical Course ◽  
Tsh Receptor ◽  
Graves Disease ◽  
Endocrine Ophthalmopathy ◽  
Post Radiation ◽  
Group 2 ◽  
Receptor Antibodies ◽  
Tsh Receptor Antibodies ◽  
Group 1

The primary objective of the present work was to study the clinical course of endocrine ophthalmopathy (EOP) following radioiodine therapy (RIT) of Graves' disease (GD) and depending on its effect (development of post-radiation hypothyroidism). The secondary objective was to determine risk factors of EOP progression after radioiodine therapy. This prospective study included 38 patients (76 eyes) allocated to two groups. The patients of group 1 (n=19/38 eyes) presented with thyrotoxicosis at each visit and continued to use thyrostatic agents; those in group 2 (n=19/38 eyes) had hypothyroidism at its early stages (3 and 6 months) and were given substitution therapy with levothyroxin. The development of post-radiation hypothyroidism was shown to strongly influence the clinical course of EOP. In the patients of group 1, EOP remained active throughout the entire observation period (12 months) in the absence of appreciable variations of its integral severity index. In group 2, the same index decreased significantly, but active forms of EOP could be detected by the time of onset of hypothyroidism (6 months) (p=0.0000). After 12 months, the level of anti-TSH receptor antibodies in the patients of group 1 was significantly higher than in those of group 2 (10.8±8.3 and 2.9±2.0 respectively, p=0.0003). The regression rate of EOP symptoms following radioiodine therapy (RIT) of Graves' disease was a function of the efficacy of thyroid 131I radioablation. It is concluded that persistence of anti-TSH receptor antibodies was responsible for the deterioration of the clinical picture of endocrine ophthalmopathy after radioiodine therapy.

Graves' disease, endocrine ophthalmopathy and smoking

1993 ◽  
Vol 128 (2) ◽  
pp. 156-160 ◽  
Author(s):  
Brita Winsa ◽  
Agneta Mandahl ◽  
F Anders Karlsson
Keyword(s):  
Confidence Interval ◽  
Odds Ratio ◽  
Eye Disease ◽  
Graves Disease ◽  
Retrospective Survey ◽  
Eye Problems ◽  
Increased Risk ◽  
Endocrine Ophthalmopathy ◽  
History Of ◽  
Receptor Antibodies

We have evaluated the association between smoking, Graves' disease and endocrine ophthalmopathy in a case-control study of 208 patients with newly diagnosed Graves' disease and carried out a retrospective survey of 72 patients treated for Graves' disease and admitted to our ward because of endocrine ophthalmopathy. In the prospective study, patients with Graves' disease smoked significantly more than their healthy controls (41% vs 30%, p<0.01 for current smokers, odds ratio 1.6, 95% confidence interval 1.1-2.3, and p<0.05 for patients with a history of smoking, odds ratio: 1.4, 95% confidence interval 1.0-1.9). Among the patients with endocrine ophthalmopathy at diagnosis, there were slightly more patients with a history of smoking (p <0.05, odds ratio 2.1, 95% confidence interval 1.1-3.9), but not more current smokers when compared with the remaining group. The patients with eye problems tended to have a more active disease with higher levels of thyroxine and TSH-receptor antibodies, but no difference was seen in thyrogastric autoantibodies. No effect of smoking on thyroid hormone and autoantibody levels could be detected. In the retrospective survey we found 64%, 71% and 87% smokers among patients with moderate, severe and malignant eye disease, respectively. In summary, the results show that smoking is associated with an increased risk of contracting Graves' disease and that it enhances the severity of the eye disease in cases that develop endocrine ophthalmopathy during the course of treatment.

Features of surgical cataract treatment in a female patient with Graves' disease and endocrine ophthalmopathy

2018 ◽  
pp. 80-86
Author(s):  
D.V. Lipatov ◽  
◽  
N.Y. Sviridenko ◽  
E.G. Bessmertnaya ◽  
A.A. Tolkachyova ◽  
...  
Keyword(s):  
Female Patient ◽  
Graves Disease ◽  
Endocrine Ophthalmopathy

Elevated anti-α-galactosyl antibody titres. A marker of progression in autoimmune thyroid disorders and in endocrine ophthalmopathy?

1987 ◽  
Vol 115 (1) ◽  
pp. 67-74 ◽  
Author(s):  
J. Etienne-Decerf ◽  
M. Malaise ◽  
P. Mahieu ◽  
R. Winand
Keyword(s):  
Antigenic Determinants ◽  
Graves Disease ◽  
Thyroid Disorders ◽  
Thyroid Disorder ◽  
Thyroid Cells ◽  
Autoimmune Thyroid ◽  
Control Subjects ◽  
Enhanced Production ◽  
Antibody Titres ◽  
Endocrine Ophthalmopathy

Abstract. The titres of anti-α-galactosyl antibodies were measured by passive haemagglutination in 50 control subjects and in 128 patients presenting with various thyroid disorders. Titres of control subjects ranged from 1/10 to 1/80, regardless of age and blood group. Elevated titres (> 1/80) were constantly noted in 6/6 patients with progressive exophthalmos, in 5/5 patients with untreated Graves' disease, and in 11/12 patients with progressive nontoxic goitre. By contrast, the titres were within the normal range in primary myxoedema (17 patients) and in residual exophthalmos (11 patients), whereas they were only erratically increased in 1/31 patients with treated or cured Graves' disease and in 5/36 patients with nonprogressive nontoxic goitre. Finally, elevated titres were also found in 3/7 patients presenting with autoimmune thyroiditis. No correlations could be established between elevated titres and the thyrotropin binding inhibiting immunoglobulin activity, the antithyroglobulin antibody titres or the antimicrosomal antibody titres. As in the control subjects, the anti-α-galactosyl antibodies mainly belonged to the IgG class. Affinity purified anti-α-galactosyl antibodies were capable of binding to trypsinized human and porcine thyroid cells in culture, as shown by indirect immunofluorescence. On the other hand, they were not able to react with untreated thyroid cells. The data show that the measurement of anti-α-galactosyl antibody titres could represent an easy and useful tool to determine whether an autoimmune thyroid disorder is in progression. Besides, they suggest that some of the antigenic determinants implicated in the enhanced production of anti-α-galactosyl antibodies are present, but normally hidden, within the cell surface of thyroid cells.

scholarly journals Anti-TSH receptor antibodies as predictors of the severity and outcome of endocrine ophthalmopathy in the patients presenting with Graves' disease

2011 ◽  
Vol 57 (2) ◽  
pp. 23-26 ◽  
Author(s):  
N Iu Sviridenko ◽  
V G Likhvantseva ◽  
I M Belovalova ◽  
M S Sheremeta ◽  
K I Tabeeva
Keyword(s):  
Thyroid Gland ◽  
Clinical Symptoms ◽  
Active Phase ◽  
Tsh Receptor ◽  
Graves Disease ◽  
Depth Analysis ◽  
Endocrine Ophthalmopathy ◽  
Inactive Phase ◽  
Receptor Antibodies ◽  
Tsh Receptor Antibodies

A total of 139 patients (278 eyes) presenting with Graves' disease (GD) and endocrine ophthalmopathy (EOP) were examined. The age of 35 men and 104 women ranged from 17 to 71 years. All of them were tested for the functional activity of the thyroid gland and underwent standard ophthalmologic examination; anti-TSH receptor antibodies were measured. Both the activity and severity of EOP were verified as recommended by the European Group on Graves' Orbitopathy (EUGOGO) It was shown that the frequency of detection of anti-TSH receptor antibodies and their titers in patients with GD and EOP depended on the activity of the intraorbital process and the severity of EOP manifestations. The functional state of the thyroid gland also influenced the level of anti-TSH receptor antibodies level during the active phase unlike that in the inactive phase. The in-depth analysis of the relationship between the level of anti-TSH receptor antibodies and clinical characteristics of either EOP (activity, severity, manifestation of selected clinical symptoms) or GD (thyrotoxicosis, euthyroidism, hypothyroidism) demonstrated the possibility to use these characteristics as the factors predicting the severity and outcome of EOP. Also, they may be helpful for the choice of a therapeutic strategy for the treatment of such patients.

scholarly journals Radioiodine therapy for Graves' disease as a risk factor of endocrine ophthalmopathy

2009 ◽  
Vol 55 (1) ◽  
pp. 51-55
Author(s):  
M S Sheremeta ◽  
I M Belovalova ◽  
N Yu Sviridenko
Keyword(s):  
Elevated Level ◽  
Radioactive Iodine ◽  
Radioiodine Therapy ◽  
Clinical Symptoms ◽  
Thyroid Stimulating Hormone ◽  
External Irradiation ◽  
Graves Disease ◽  
Endocrine Ophthalmopathy ◽  
Eye Symptoms ◽  
The Relationship

In 1973 and 1976 R. Wasnich and R. Jackson described 2 cases of endocrine ophthalmopathy (EO) that occurred after external irradiation of the anterior surface of the neck due to a tumor (Hodgkin's lymphoma). Further observations showed that treatment of Graves' disease with radioactive iodine (131I) can worsen the course of EO. So, L. De Groot et al., Observing 264 patients after exposure to 131I for Graves' disease, found progression of EO in 4% of patients after the 1st course of therapy and in 12% after subsequent sessions. L. Bartalena et al. observed the appearance or significant progression of EO in 15% of 150 patients treated with 131I. At the same time, against the background of glucocorticoid therapy, only 10% of patients worsened the course of EO. Other studies have shown that the progression of EO after treatment with 131I without glucocorticoid administration was observed in 18-30% of cases. Along with this, it is believed that 131I does not affect the incidence of clinical symptoms in the orbit, and hypothyroidism that occurs after it does not lead to the progression of eye symptoms. The relationship between treatment and the onset or progression of EO is not clear. Nevertheless, there is evidence of an adverse effect of an elevated level of antibodies to the thyroid stimulating hormone receptor (TSH) in the blood serum after 1131I training for EO. This review is devoted to a review of the problem presented.

Association of CTLA4 and TNF gene polymorphisms with endocrine ophthalmopathy in ethnic Russian patients with Graves’ disease

2015 ◽  
Vol 87 (10) ◽  
pp. 67 ◽  
Author(s):  
N. S. Martirosian ◽  
A. M. Burdennyi ◽  
L. V. Trukhina ◽  
O. G. Panteleeva ◽  
S. V. Saakyan ◽  
...  
Keyword(s):  
Gene Polymorphisms ◽  
Graves Disease ◽  
Endocrine Ophthalmopathy ◽  
Tnf Gene
Sign in / Sign up

Export Citation Format

Share Document